title: 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period.
abstract: The aim of our study was to determine if the generation of thromboxane is altered in patients with peripheral arterial occlusive disease following percutaneous transluminal angioplasty (PTA) during a one year follow-up period. In this study, 175 patients diagnosed with peripheral arterial occlusive disease (PAOD) and demonstrating short-distance claudication or ischemic rest pain, requiring PTA in either the iliac, femoral, or popliteal arteries, were enrolled. The excretion of 11-dehydro thromboxane B2 (TXB2) was measured in urine samples by high-performance liquid chromatography-mass spectrometry and recalculated based on the creatinine concentration. The urine samples were collected the morning prior to PTA, immediately following PTA and the day after PTA. All of the study subjects were then observed for a period of 12 months. Urine samples were also collected during the follow-up visits, and the levels of 11-dehydro TXB2 were measured at 1 month (1458.1 pg/mg creatinine ± 1240.8), 3 months (1623.3 pg/mg creatinine ± 1362.2), 6 months (1314.8 pg/mg creatinine ± 1378.7) and 12 months (1473.2 pg/mg creatinine ± 1455.2) after the PTA procedure. All of the patients were taking 75 mg of aspirin per day throughout the course of the study, as well as 75 mg of clopidogrel for six weeks following PTA. Overall, the mean TXB2 values immediately after PTA were significantly higher than either before the procedure (1524.4 pg/mg creatinine ± 1411.1 vs. 2098.1 pg/mg creatinine ± 1661.8; P = 0.00002), the day after PTA, or at any other point during the study. Moreover, preoperative TXB2 levels correlated well with the composite endpoints of death, myocardial infarction and stroke during the follow-up period (OR 7.42 [CI 95% = 1.2-48.8]; P = 0.02). Our findings suggest that clinicians should consider the use of TXA2 synthase inhibitors and receptor antagonists in combination with peripheral percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease.
authors: Department of Angiology, 2nd Chair of Internal Medicine, Jagiellonian University Medical College, Cracow, Poland. maga.pawel@gmail.com.
authors: P
authors: P
authors: Maga
authors: Department of Molecular Biology, 2nd Chair of Internal Medicine, Jagiellonian University Medical College, Cracow, Poland.
authors: M
authors: M
authors: Sanak
authors: Chair of Pharmacology, Jagiellonian University Medical College, Cracow, Poland.
authors: J
authors: J
authors: Jawien
authors: Jagiellonian University Medical College, Cracow, Poland.
authors: B
authors: B
authors: Rewerska
authors: Jagiellonian University Medical College, Cracow, Poland.
authors: M
authors: M
authors: Maga
authors: Jagiellonian University Medical College, Cracow, Poland.
authors: A
authors: A
authors: Wachsmann
authors: Jagiellonian University Medical College, Cracow, Poland.
authors: M
authors: M
authors: Koziej
authors: Jagiellonian University Medical College, Cracow, Poland.
authors: I
authors: I
authors: Gregorczyk-Maga
authors: Department of Angiology, 2nd Chair of Internal Medicine, Jagiellonian University Medical College, Cracow, Poland.
authors: R
authors: R
authors: Nizankowski
mesh_terms: D000368:Aged; D017130:Angioplasty; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D058729:Peripheral Arterial Disease / Q000628:therapy / Q000652:urine*; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine
chemical_list: D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2